1.Study on surface microcirculation sensitization of acupuncture points related to cold coagulation and stasis syndrome in primary dysmenorrhea
Xuxin LI ; Xuesong WANG ; Miao LIN ; Mingjian ZHANG ; Yuanbo GAO ; Xifen ZHANG ; Hao CHEN ; Haiping LI ; Xiaojun ZHENG ; Xisheng FAN ; Jun LIU ; Juncha ZHANG ; Yanfen SHE
Journal of Beijing University of Traditional Chinese Medicine 2025;48(2):253-269
Objective:
To assess the dynamic changes of microcirculation at acupoints in patients with primary dysmenorrhea and cold congelation and blood stasis syndrome using laser speckle blood flow imaging.
Methods:
Patients with primary dysmenorrhea and cold coagulation and blood stasis syndrome (primary dysmenorrhea group, n=53) and healthy female college students(control group, n=57) who met the inclusion and exclusion criteria from October 2020 to July 2022 were enrolled at Hebei University of Chinese Medicine. On the premenstrual and first day of menstruation, a laser speckle blood flow imaging system was used to measure the microcirculation blood flow perfusion on the surface of acupoints related to the conception, thoroughfare, and governor vessels, and stomach, spleen, and bladder meridians in the abdomen and lumbosacral regions. The dynamic changes in microcirculation were calculated based on the difference in average blood flow perfusion at each acupoint before and after menstruation. Receiver operating curve (ROC) analysis was used to analyze the diagnostic efficacy of dynamic changes in microcirculation on the surface of each acupoint. The microcirculation sensitization rate of acupoints was calculated.
Results:
Compared with the control group, the dynamic changes in microcirculation at the following acupoints in the primary dysmenorrhea group were increased (P<0.05): conception vessel (Yinjiao[CV7], Qihai[CV6], Shimen[CV5], Guanyuan[CV4]); left thoroughfare vessel (left Huangshu[KI16], left Zhongzhu[KI15], left Siman[KI14], left Qixue[KI13], left Dahe[KI12], left Henggu[KI11]); left stomach meridian (left Tianshu[ST25], left Wailing[ST26], left Qichong[ST30]); left spleen meridian (left Daheng[SP15], left Fujie[SP14]); right thoroughfare vessel (right Huangshu[KI16], right Zhongzhu[KI15], right Siman[KI14], right Qixue[KI13], right Dahe[KI12], right Henggu[KI11]); right stomach meridian (right Wailing[ST26], right Daju[ST27], right Shuidao[ST28], right Guilai[ST29], right Qichong[ST30]); and right spleen meridian (right Fujie[SP14]). The area under the ROC curve of conception vessel (Yinjiao[CV7], Qihai[CV6], Shimen[CV5], Guanyuan[CV4]), thoroughfare vessel (right Siman[KI14], left Huangshu[KI16], right Qixue[KI13], right Zhongzhu[KI15], right Dahe[KI12], left Zhongzhu[KI15], left Siman[KI14], right Huangshu[KI16], left Qixue[KI13], right Henggu[KI11], left Henggu[KI11], left Dahe[KI12]); stomach meridian (left Tianshu[ST25], right Guilai[ST29], left Wailing[ST26], right Shuidao[ST28], right Daju[ST27], right Wailing[ST26], right Qichong[ST30], left Qichong[ST30]), and spleen meridian (left Daheng[SP15], left Fujie[SP14], right Fujie[SP14]) was 0.610-0.682 (P<0.05). Compared with the control group, the sensitization rate of some acupoints in the primary dysmenorrhea group increased (P<0.05).
Conclusion
With the onset of menstruation, the blood flow perfusion of some acupoints in the abdomen (thoroughfare, and conception vessels, and stomach and spleen meridians) of patients with primary dysmenorrhea and cold blood coagulation and blood stasis syndrome increased, and the status of acupoints changed from a resting state to an active state. These acupoints are sensitive in patients with primary dysmenorrhea and cold blood coagulation and blood stasis syndrome and have a certain diagnostic efficacy, providing a basis for further analyzing the efficacy and mechanism of acupuncture and moxibustion to treat primary dysmenorrhea with cold blood coagulation and blood stasis syndrome.
2.Traditional Chinese Medicine Prevents and Treats Cerebral Ischemia-reperfusion Injury by Regulating Nrf2 Signaling Pathway: A Review
Siqing WU ; Jun WANG ; Mingsan MIAO ; Jinxin MIAO
Chinese Journal of Experimental Traditional Medical Formulae 2025;31(13):286-295
Cerebral ischemia-reperfusion injury (CIRI), a common cerebrovascular disease damage, has garnered increasing attention in the treatment of acute ischemic stroke. Restoration of blood flow and reperfusion to ischemic brain tissue is the key to treatment, while this process often triggers a variety of complex pathophysiological responses, such as oxidative stress, apoptosis, inflammation, mitochondrial dysfunction, angiogenic abnormalities, and disruption of the blood-brain barrier. These responses not only impede the recovery of neurological functions but also may lead to damage or even death of nerve cells, seriously affecting the neurological function and quality of survival of patients. As an important transcription factor, nuclear factor E2-related factor 2 (Nrf2) has the pharmacological effect of alleviating CIRI by regulating antioxidant, anti-apoptosis, anti-inflammation, mitochondrial function, angiogenesis, and blood-brain barrier pathways. This reveals the potential mechanism of traditional Chinese medicine (TCM) in intervening in CIRI and shows the potential of Nrf2 as a new pathway for dealing with ischemia stroke. This paper comprehensively analyzes the effects and mechanisms of active components and compound prescription of TCM in treating CIRI by modulating the Nrf2 signaling pathway, while pointing out the shortcomings of available studies and proposing a multidimensional exploration. This review aims to provide patients with more comprehensive, safe, and effective therapeutic regimens and improve the quality of survival and prognosis of patients. In addition, in-depth research on TCM should be promoted to reveal the potential mechanism for treating CIRI, providing new ideas and directions for the development of novel therapeutic drugs and methods.
3.Traditional Chinese Medicine Prevents and Treats Cerebral Ischemia-reperfusion Injury by Regulating Nrf2 Signaling Pathway: A Review
Siqing WU ; Jun WANG ; Mingsan MIAO ; Jinxin MIAO
Chinese Journal of Experimental Traditional Medical Formulae 2025;31(13):286-295
Cerebral ischemia-reperfusion injury (CIRI), a common cerebrovascular disease damage, has garnered increasing attention in the treatment of acute ischemic stroke. Restoration of blood flow and reperfusion to ischemic brain tissue is the key to treatment, while this process often triggers a variety of complex pathophysiological responses, such as oxidative stress, apoptosis, inflammation, mitochondrial dysfunction, angiogenic abnormalities, and disruption of the blood-brain barrier. These responses not only impede the recovery of neurological functions but also may lead to damage or even death of nerve cells, seriously affecting the neurological function and quality of survival of patients. As an important transcription factor, nuclear factor E2-related factor 2 (Nrf2) has the pharmacological effect of alleviating CIRI by regulating antioxidant, anti-apoptosis, anti-inflammation, mitochondrial function, angiogenesis, and blood-brain barrier pathways. This reveals the potential mechanism of traditional Chinese medicine (TCM) in intervening in CIRI and shows the potential of Nrf2 as a new pathway for dealing with ischemia stroke. This paper comprehensively analyzes the effects and mechanisms of active components and compound prescription of TCM in treating CIRI by modulating the Nrf2 signaling pathway, while pointing out the shortcomings of available studies and proposing a multidimensional exploration. This review aims to provide patients with more comprehensive, safe, and effective therapeutic regimens and improve the quality of survival and prognosis of patients. In addition, in-depth research on TCM should be promoted to reveal the potential mechanism for treating CIRI, providing new ideas and directions for the development of novel therapeutic drugs and methods.
4.Monitoring and analysis of eye lens dose of interventional radiology workers
Qiuqiu PAN ; Jun DENG ; Mengxue LI ; Xiaohua MIAO ; Lingling ZHENG ; Yajuan FENG ; Senxing ZHENG
Chinese Journal of Radiological Health 2025;34(3):384-389
Objective To investigate the levels and influencing factors for eye lens dose of interventional radiology workers, and to provide a basis for reasonable and scientific radiation protection. Methods Thermoluminescent eye lens dosimeters were used to monitor the left and right eye lens doses of interventional radiology workers in real time during different surgical positions and varying eye protection conditions. The annual eye lens doses for the operators were estimated based on their yearly workload. The differences in eye lens doses under different conditions were analyzed and the influencing factors were identified. Results For individual interventional operations, the range of personal dose equivalent Hp(3) of the left eye of interventional radiology workers was ( < MDL ~ 418.33) μSv, the median (Q1, Q3) was 9.29 ( < MDL, 40.79) μSv, and the mean was 40.79 ± 70.36 μSv. The estimated annual eye lens doses were 4.05 mSv and 17.80 mSv based on the median and mean values of the eye lens dose of a single operation multiplied by average annual frequency of operations per person, respectively. The left eye lens dose was higher than the right eye lens dose of the same operator (Z = −4.24, P < 0.05), and the dose of the right eye lens was strongly positively correlated with that of the left eye lens. The left eye lens dose of the first surgeon was higher than that of the second surgeon in the same operation (Z = −3.10, P < 0.05). The eye lens dose was influenced by operator position (χ2 = 9.149, P = 0.002, OR = 8.343), eye protection (χ2 = 4.619, P = 0.032, OR = 4.352), and air kerma area product (χ2 = 8.032, P = 0.005, OR = 5.488). Conclusion According to the results of this study, a significant portion of interventional operators have eye lens doses that approach or exceed international occupational dose limits. It is recommended to pay attention to the operation frequency of the first operator and the air kerma area product of interventional operation, and strengthen radiation protection and dose monitoring for the eye lens of interventional radiology workers.
5.Clinical efficacy of camrelizumab combined with apatinib versus camrelizumab combined with chemotherapy regimens as first-line treatment for advanced gastric cancer
Ran JU ; Qi MIAO ; Jun YANG ; Yonggui WANG ; Xiangning DONG
China Pharmacy 2025;36(18):2307-2311
OBJECTIVE To compare the clinical efficacy and safety of camrelizumab combined with apatinib versus camrelizumab combined with chemotherapy as first-line treatment for advanced gastric cancer. METHODS A prospective randomized controlled trial was conducted, enrolling 99 patients with advanced gastric cancer admitted to the Chuzhou First People’s Hospital from March 2022 to December 2024. Patients were randomly assigned using a random number table: 48 received camrelizumab plus chemotherapy (control group), and 51 received camrelizumab plus apatinib (observation group). Clinical efficacy, serum tumor marker[carcinoembryonic antigen(CEA),carbohydrate antigen(CA)724,CA199,CA242]levels, immune function indicators(CD3+,CD4+,CD8+,CD4+/CD8+) levels before and after treatment, and adverse drug reaction (ADR) during treatment were compared between the 2 groups. RESULTS A total of 2 patients in the observation group and 3 in the control group were lost to follow-up. The disease control rate and objective response rate in the observation group were 95.92% and 85.71%, respectively, both significantly higher than 80.00% and 55.56% in the control group (P<0.05). The median progression-free survival was 9.61 months in the observation group, significantly longer than 6.72 months in the control group (P=0.011). Before treatment, there was no statistically significant difference in the levels of serum tumor markers and immune function indicators between the 2 groups (P>0.05). After treatment, the levels of CEA, CA724, CA199 and CA242 in 2 groups were significantly lower than before treatment, while the levels of CD3⁺, CD4⁺ and CD4 ⁺/CD8 ⁺ were significantly higher than before treatment, with greater improvements in the observation group (all P<0.05). The overall incidences of ADR and severe ADR showed no statistically significant difference between the 2 groups (P>0.05). CONCLUSIONS Camrelizumab combined with apatinib as first-line therapy for advanced gastric cancer may offer advantages over camrelizumab plus chemotherapy in terms of clinical efficacy and immune function improvement of patients, with an acceptable safety profile.
6.Alleviation of sleep deprivation-induced hyper sleepiness and cognitive impairment by pitolisant, a histamine H3 receptor inverse agonist
Yan ZHAO ; Jun WEI ; Chaoyu MIAO
Journal of Pharmaceutical Practice and Service 2025;43(10):491-495
Objective To investigate the effects of the H3 receptor inverse agonist pitolisant on wakefulness and cognitive behavior in mice subjected to sleep deprivation, and assess its potential wake-promoting and pro-cognitive properties. Methods A mouse model of sleep deprivation was utilized, in which sleep deprivation was performed for 6, 12, and 24 h by an automatic rotating rod system. Pitolisant (20 mg/kg, i.p.) or saline control was administered prior to the end of deprivation. Quantitative wakefulness was monitored by polysomnographic recordings and spontaneous locomotion, spatial learning and memory were assessed through open field test and Morris water maze test, respectively. Results Pitolisant significantly increased wake duration after all sleep deprivation periods, with the most prominent effect observed in the early recovery phase. In the 24 h deprivation model, pitolisant also significantly improved spontaneous locomotor activity and showed a potential enhancement of spatial learning and memory, although the effects did not reach statistical significance. Conclusion Pitolisant not only enhanced wakefulness but also showed partial pro-cognitive effects following sleep loss, which supported its potential application in improving cognitive impairment associated with various sleep disorders.
7.Exploration on the paths of medical ethics education for medical students from the perspective of youth moral cultivation
Yuancong OUYANG ; Fang DONG ; Jun LI ; Miao GAO ; Haiyan LIU ; Qiuyu YANG
Chinese Medical Ethics 2025;38(11):1492-1497
The view of youth moral cultivation clearly defines the scope of “morality” and puts forward the requirement of “cultivating morality” for the youth. This is a systematic concept aligned with the main theme of the times and is worth deeply exploring and integrating into the practice of medical ethics education for medical students. With the requirements for innovation and development in medical education, the cultivation of medical students has also been endowed with new connotations. Guided by the connotations of the view of youth moral cultivation and aligned with the objective requirements of medical students’ cultivation, this paper leveraged the core values of traditional Chinese medicine as its entry point. It also explored the realization paths of medical ethics education for medical students that reflect advantages, highlight characteristics, and maintain clear orientation through strengthening the medical ethics education of “dedicated study of medicine,” “honesty and prudence in words and deeds,” “benevolence in heart and skills,” and “doctor-patient trust and harmony,” aiming to cultivate guardians of people’s health with noble medical ethics and superb medical skills.
8.Effects of hydroxysafflor yellow A on autophagy in bEnd.3 cells after oxygen-glucose deprivation
Yao-Yao DAI ; Meng-Qi SHU ; Ru-Heng WEI ; Zhu-Yue MIAO ; Zhi-Bin DING ; Dong MA ; Jian-Jun HUANG ; Li-Juan SONG ; Cun-Gen MA
The Chinese Journal of Clinical Pharmacology 2024;40(12):1734-1738
Objective To explore the effect and mechanism of hydroxysafflor yellow A(HSYA)on autophagy in bEnd.3 cells after oxygen-glucose deprivation(OGD).Methods The bEnd.3 cells were divided into normal group(conventional culture),model group(OGD model),HSYA group(OGD model+75 μmol·L-1 HSYA),3-methyladenine(3MA)group(5 mmol·L-1 3MA+OGD model)and 3 MA+HSYA group(5 mmol·L-1 3 MA+OGD model+75 μmol·L-1 HSYA).The level of apoptosis was determined by TUNEL fluorescence staining;Western blot was used to detect the expression of autophagy,blood brain barrier(BBB)related proteins;real time fluorescence quantitative polymerase chain reaction method for determining the expression of sirtuin-1(SIRT1)and forkhead box protein O3a(FOXO3A)mRNA.Results In the normal group,model group,HSYA group,3MA group and 3MA+HSYA group,the positive cells selected for TUNEL staining were 5.00±1.00,28.00±2.00,21.00±3.00,35.33±2.51 and 29.67±2.52;the expression levels of microtubule-associated protein 1 light chain 3-Ⅱ/-Ⅰ(LC3-Ⅱ/-Ⅰ)were 0.90±0.20,1.34±0.10,1.95±0.14,0.76±0.15 and 1.14±0.09;sequestosome 1(P62)were 0.99±0.02,0.60±0.02,0.38±0.01,0.67±0.04 and 0.54±0.01;occludin were 1.39±0.17,0.62±0.15,1.00±0.09,0.40±0.13 and 0.80±0.15;zonula occludens-1(ZO-1)were 1.63±0.20,0.64±0.06,0.98±0.14,0.37±0.14 and 0.87±0.04;SIRT1 mRNA were 1.00±0.00,0.75±0.07,1.69±0.09,0.31±0.02 and 0.56±0.01;FOXO3A mRNA were 1.00±0.00,0.80±0.05,1.47±0.09,0.40±0.01 and 0.62±0.09,respectively.Significant differences were found between model group and normal group,HSYA group and model group,3MA+HSYA group and 3MA group(P<0.05,P<0.01,P<0.001).Conclusion HSYA may enhance autophagy levels in bEnd.3 cells after OGD through the SIRT1/FOXO3A pathway,inhibit cell apoptosis and alleviate BBB damage.
9.Research on population pharmacokinetics of propofol injection in adult patients under general anesthesia
Jin-Xia LI ; An-Cheng GU ; Fu-Miao YUAN ; Cai LI ; Hai-Jun DENG ; Zhong-Yuan XU
The Chinese Journal of Clinical Pharmacology 2024;40(14):2124-2128
Objective To quantitatively assess the influence of various factors on the pharmacokinetic parameters of propofol and to develop a propofol population pharmacokinetic model tailored for Chinese patients.Methods Thirty patients scheduled for selective abdominal surgeries received an anesthesia dose of propofol at 2.0 mg·kg-1.The concentration of propofol in collected venous blood samples was measured using liquid chromatography-tandem mass spectrometry.Polymorphisms in metabolizing enzyme genes were detected through Sanger sequencing technology.Pharmacokinetic parameters were computed,and models were constructed and evaluated using Phoenix Winnonlin software.Results Through software analysis,the drug's in vivo process was best described by a three-compartment model.The population mean values for the central compartment clearance rate(CL),shallow peripheral compartment clearance rate(Q2),deep peripheral compartment clearance rate(Q3),central compartment volume of distribution(V),shallow peripheral compartment volume of distribution(V2),and deep peripheral compartment volume of distribution(V3)were 1.71 L·min-1,1.31 L·min-1,1.51 L·min-1,5.92 L,19.86 L and 99.06 L,respectively.Body weight was identified as a significant covariate affecting CL and V,and was incorporated into the model.Conclusion The evaluation of the final model demonstrates its substantial predictive capability,offering directional guidance for the clinical administration of propofol.
10.Evidence-based guideline for the management of clinical application of biosimilars in China (2024 edition)
Zaiwei SONG ; Yang HU ; Lingling YU ; Jun ZHU ; Lingli ZHANG ; Yu ZHANG ; Liyan MIAO ; Suodi ZHAI ; Rongsheng ZHAO
China Pharmacy 2024;35(16):1933-1945
OBJECTIVE To provide standardized guidance for the clinical application and management of biosimilars, and promote their widespread and rational use in clinical treatment. METHODS The design, planning, and drafting process as well as the full report of Evidence-based Guideline for the Management of Clinical Application of Biosimilars in China (2024 Edition) followed the WHO Handbook for Guideline Development (2nd edition), which fully considered the best current evidence from evidence-based medicine, multidisciplinary expert experience, and patient preferences and values. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was adopted to evaluate the quality of evidence and determine the strength of recommendations. RESULTS & CONCLUSIONS Evidence-based Guideline for the Management of Clinical Application of Biosimilars in China (2024 Edition) presented 10 recommendations including 7 strong recommendations and 3 weak recommendations. The recommendations covered the entire process of clinical application and management of biosimilars. Medical institutions and relevant health regulatory departments can refer to this guideline for the scientific management of the extrapolation of unapproved indications of biosimilars. Healthcare providers can refer to this guideline for pre-treatment assessments, patient education, pre-treatment regimen before administration, and dosage regimen adjustments. Multidisciplinary medical teams can refer to this guideline to provide pharmacovigilance and patient management throughout the treatment process.


Result Analysis
Print
Save
E-mail